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Carotid arterySympathetic nerve activity regulates blood pressure by altering peripheral vascular resistance. Variations in
vascular sympathetic innervation suggest that vascular-derived cues promote selective innervation of
particular vessels during development. As axons extend towards peripheral targets, they migrate along
arterial networks following gradients of guidance cues. Collective ratios of these gradients may determine
whether axons grow towards and innervate vessels or continue past non-innervated vessels towards
peripheral targets. Utilizing directed neurite outgrowth in a three-dimensional (3D) co-culture, we observed
increased axon growth from superior cervical ganglion explants (SCG) towards innervated compared to non-
innervated vessels, mediated in part by vascular endothelial growth factor (VEGF-A) and Semaphorin3A
(Sema3A) which both signal via neuropilin-1 (Nrp1). Exogenous VEGF-A, delivered by high-expressing
VEGF-A–LacZ vessels or by rhVEGF-A/alginate spheres, increased sympathetic neurite outgrowth while
exogenous rhSema3A/Fc decreased neurite outgrowth. VEGF-A expression is similar between the innervated
and non-innervated vessels examined. Sema3A expression is higher in non-innervated vessels. Spatial
gradients of Sema3A and VEGF-A may promote differential Nrp1 binding. Vessels expressing high levels of
Sema3A favor Nrp1-PlexinA1 signaling, producing chemorepulsive cues limiting sympathetic neurite
outgrowth and vascular innervation; while low Sema3A expressing vessels favor Nrp1-VEGFR2 signaling
providing chemoattractive cues for sympathetic neurite outgrowth and vascular innervation.
© 2009 Published by Elsevier Inc.Introduction
Sympathetic regulation of blood pressuremaintains cardiovascular
homeostasis and responsiveness to physical stress. Major feed arteries
and precapillary arterioles are innervated, whereas capillaries, venules
and collecting veins are sparsely innervated (Birch et al., 2008;
Fleming et al., 1989; Grasby et al., 1999; Ruffolo et al., 1991; Tan et al.,
2007). Variations in vascular sympathetic innervation suggest that
vascular-derived guidance cues expressed during development
determine patterns of innervation.
Axon extension from developing sympathetic neurons often
follows arterial networks towards more peripheral targets (Glebova
and Ginty, 2005) but little is known about how vessels themselves are
selected as targets for innervation. Axon outgrowth and target
innervation are governed by gradients of guidance cues that can be
local, long-range, contact-mediated, secreted, attractive or repulsive
(Tessier-Lavigne and Goodman, 1996). Guidance cues include growth
factors, extracellular matrix molecules and “classical” axon guidance
molecules (netrins, slits, semaphorins, and ephrins) (Young et al.,
2004). Disruption of single signaling pathways results in complexlsevier Inc.inhibitory proﬁles suggesting that multiple molecules govern inner-
vation patterns (Belliveau et al., 1997; Glebova and Ginty, 2004;
Kuruvilla et al., 2004). Vascular cells express neurotrophins and axon
guidance molecules, known to affect vascular morphogenesis and
angiogenesis as well as axon outgrowth and guidance (Adams et al.,
1999; Carmeliet, 2003; Enomoto et al., 2001; Herzog et al., 2001;
Honma et al., 2002).
Angiogenic factors exert neurotrophic and neuroprotective effects
in-vivo and in-vitro (Cheng et al., 2004; Rosenstein and Krum, 2004;
Schwarz et al., 2004; Sondell and Kanje, 2001; Sondell et al., 1999;
Sondell et al., 2000; Storkebaum et al., 2005; Wingerd et al., 2002).
VEGF-A promotes axon outgrowth and neuronal survival in-vitro by
paracrine and autocrine pathways in dorsal root ganglion (DRG) and
SCG via ﬂk-1 (VEGFR2) signaling (Ogunshola et al., 2002; Lin et al.,
2003; Sondell and Kanje, 2001) and has been shown to modulate
sympathetic growth cone collapse and spreading and promote re-
innervation following local nerve damage (Damon, 2006; Marko and
Damon, 2008).
Nrp1, a co-receptor for VEGFR2, is implicated in VEGF-A signaling
(Soker et al., 1998) and is also a receptor for Sema3A, a chemor-
epulsive factor that causes growth cone collapse and axon repulsion
and has been implicated in modulating vascular sympathetic
innervation (Fan and Raper, 1995; He and Tessier-Lavigne, 1997;
120 J.B. Long et al. / Developmental Biology 334 (2009) 119–132Kolodkin et al., 1997). Sema3A or Nrp1 inactivation causes decreased
peripheral target innervation (Kitsukawa et al., 1997). While previous
in-vitro studies suggested competitive binding of Nrp1 by VEGF-A and
Sema3A (Appleton et al., 2007; Geretti et al., 2008; Miao et al., 1999),
more recent in-vivo data suggests that this may not be the case.
Instead, in-vivo, VEGF-A and Sema3A may direct vessel and axon
growth in a context dependent manner, which is determined by the
localization or concentration of these Nrp1 ligands in a given
environment (Schwarz et al., 2004; Vieira et al., 2007). For example,
in the facial nerve, Sema3A is required for proper pathﬁnding of facial
motor axons while VEGF-A is required for the proper migration of
their somata (Schwarz et al., 2004). In neural progenitor cells, both
VEGF-A and Sema3A reciprocally antagonize the opposing signaling
pathway, suggesting that their relative concentrations may determine
cellular behaviors including migration, proliferation and apoptosis
(Bagnard et al., 2001). Thus, both vessel-derived VEGF-A and Sema3A
may inﬂuence sympathetic innervation patterning depending on
speciﬁc ligand–receptor interactions.
Here, we evaluate directed sympathetic neurite outgrowth
towards innervated and non-innervated vessels in an in-vitro 3D co-
culture system. We hypothesize that both VEGF-A and Sema3A drive
selective sympathetic neurite outgrowth and may play a role in
determining vascular innervation during development. Our results
suggest that vascular-derived VEGF-A and Sema3A independently
inﬂuence sympathetic neurite outgrowth and demonstrate higher
Sema3A expression in non-innervated vessels, which coupled with
the effect of exogenous Sema3A and VEGF-A on neurite growth
suggests that Sema3A signaling exerts the predominant molecular
inﬂuence and may promote sympathetic innervation of particular
vessels in-vivo by reducing axon outgrowth towards sparsely
innervated vessels.
Materials and methods
Mice
CD-1 mice were obtained from Charles River Laboratories (CRL
Wilmington, MA) or laboratory stock derived from CRL breeders.
VEGF-A (hi/+) mice, a generous gift from Dr. A. Nagy, (University of
Toronto, Ontario, Canada) were generated as previously described
(Miquerol et al., 1999; Nordal et al., 2004; Pinter et al., 2001) and bred
in our animal facility. Speciﬁcally, VEGF-A–LacZ knock-in mice were
generated by inserting an internal ribosome entry site (IRES)-LacZ
cassette into the 3′ UTR (exon 8) of VEGF-A. This strategy permits the
production of two functional proteins, VEGF-A and LacZ, from a single
bicistronic transcript (Miquerol et al., 1999; Nordal et al., 2004; Pinter
et al., 2001). In addition, addition of the LacZ cassette results in
increased stability of VEGF-A mRNA, resulting in increased VEGF-A
protein expression (Miquerol et al., 1999, 2000). Isolated vascular
smooth muscle cells were isolated from mice expressing EYFP under
the promoter for transgelin, a smooth muscle cell actin binding
protein. Tg (Tagin-cre) 1HER mice on a mixed C57BL/6, SJL back-
ground (Jackson Laboratory, Bar Harbor, ME) were backcrossed to the
conditional ROSA26-EYFP reporter strain (Srinivas et al., 2001).
Immunoﬂuorescence
Femoral and carotid arteries were dissected from adult CD-1 mice,
ﬁxed in 4% paraformaldehyde in PBS (PFA), passed through a sucrose
gradient as described (Li et al., 2007) and embedded in Tissue-Tek O.C.
T Compound. 10 μm cryosections were incubated in blocking buffer
(10% normal goat serum, 3% fetal bovine serum, 0.3% bovine serum
albumin, 0.1% Triton-X in PBS) for 1 h before being transferred into
primary antibody solution (rat anti-mouse PECAM-1, cat. # 550274,
BD Biosciences, San Jose, CA; mouse anti-mouse smooth muscle alpha
actin-Cy3 conjugated, cat. # C-6198, Sigma-Aldrich, St. Louis, MO;rabbit anti-mouse tyrosine hydroxylase, cat. # AB152, Chemicon,
Temecula, CA; goat anti-rat vesicular acetylcholine transporter
(VAChT), cat. # AB1578, Chemicon; and mouse anti-mouse synapto-
physin, cat. # MAB5258, Chemicon) in blocking buffer overnight at
4 °C. Sections were washed and incubated in secondary antibody
solution (Alexa Fluor 488 goat anti-rabbit, cat. # A11008; 594 goat
anti-rabbit, cat. # A11012; 488 goat anti-rat, cat. # A11007; and 594
goat anti-mouse, cat. # A11005; Invitrogen, Carlsbad, CA) for 1 h.
Coverslips were mounted with Vectashield containing DAPI (Vector
Labs, Burlingame, CA).
VEGF-A (hi/+) innervation analysis
Femoral and carotid arteries were dissected from adult and
postnatal day 16 mice, ﬁxed, cryosectioned and stained for tyrosine
hydroxylase immunoreactivity as described above. Total ﬂuorescence
intensity (integrated density) for tyrosine hydroxylase and the
number of TH positive puncta were measured for each vessel using
NIH ImageJ and divided by the vessel perimeter to calculate
innervation density (intensity/μm) or # TH positive puncta (# TH
positive puncta/μm).
Postnatal innervation analysis
Femoral and carotid arteries were dissected from mice between
postnatal days 0–9, and were ﬁxed in 4% PFA. Whole vessels were
incubated in whole mount blocking buffer (4% normal goat serum,
0.1% Triton-X in PBS) for 1 h and then in primary antibody (rabbit
anti-mouse tyrosine hydroxylase, cat. # MAB5258, Chemicon) over-
night at 4 °C. Vessels were washed and incubated in the appropriate
secondary antibody. To quench auto ﬂuorescence, tissues were
incubated in 0.05% Pontamine Sky Blue (Sigma-Aldrich) in PBS for
20 min. Vessels were then pinned at in situ dimensions on Sylgard®
(#184; Dow Corning Corp., Midland, MI) on a glass slide. Innervation
densities were determined by capturing image stacks with 2 μm steps
through the Z-axis of the vessel using a Zeiss Axiovert 200 (10×
objective) coupled to Axiovision software. Images were transferred
into the NeuroLucida system (MicroBrightField, Williston, VT), which
was used to trace the total nerve length on the superﬁcial half of each
vessel. Individual axons were joined artiﬁcially at nodes to produce a
single nerve network with a spatial resolution of approximately 1 μm
using NeuroExplorer (MicroBrightField, Williston, VT). Vessel surface
area was determined by outlining each vessel to calculate the major
and minor radii as well as the length of the vessel. Innervation
density was then calculated as total nerve length (μm)/surface area
of vessel (μm2).
SCG explant co-culture
SCG were isolated from postnatal day 2 CD-1 mice. Non-neuronal
cells were growth arrestedwithmitomycin C for 1 h (10 μg/ml, Sigma-
Aldrich, St. Louis, MO). Carotid and femoral artery segments were
harvested from adult CD-1 mice. Vessels were cleaned of adventitia
and cut into 5 mm segments. Neurovascular co-cultures were
embedded in type I collagen gel (150 μl, 2.5 mg/ml acid soluble
bovine calf skin collagen (Madri et al., 1988)) in each well of a 24-well
plate (as illustrated in Figs. 2A–C). Cultureswere grown in a co-culture
medium (DMEM/F12, 10% fetal bovine serum, 2 mM L-glutamine,
2 mM penicillin/streptomycin, and 20 ng/ml NGF) for 16 h (5% CO2,
37 °C). For VEGF-A hypermorph co-cultures, femoral and carotid
artery segments were isolated from VEGF-A (hi/+) mice. To block
VEGF-A released from vessels, blocking antibodies directed towards
human recombinant VEGF-A (R&D Systems) were used (1 μg/ml).
Three independent experiments were performed that each included
4–5 SCG explants per culture condition (total n=14). To block VEGF-
A and/or Sema3A from vessel segments, a highly speciﬁc VEGFR2
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al., 1988), a function-blocking VEGFR1 neutralizing antibody (cat. #
AF471, monoclonal anti-mouse VEGFR1, R&D Systems, Minneapolis,
MN) or a function-blocking Nrp1 neutralizing antibody (cat. # AF566,
anti-rat Nrp1, R&D Systems) was added to the media in indicated
concentrations (total n=10–14).
Imaging and morphological analysis
Ganglia were ﬁxed in 4% PFA for 20 min at room temperature and
visualized using an inverted light microscope (IX71-SIF; Olympus,
Center Valley, PA) with CplanFL 4× NA 0.13 objective (Olympus) and
captured with a digital camera (S97809; Olympus) using Picture
Frame acquisition software (Optronics, Goleta, CA). Each SCG was
divided into quadrants and images were obtained in the quadrants
directed towards the femoral and carotid arteries (Fig. 2B). Average
axon length (μm, 25 axons randomly selected per quadrant) was
determined using NIH ImageJ. Ratios of directed neurite outgrowth
were calculated to allow normalization across individual SCG
explants. In outgrowth ratios represent outgrowth towards the
innervated vessel (femoral) relative to that seen for the non-
innervated vessel (carotid) except in instances where two carotid
segments or two femoral segments are compared. In these instances,
outgrowth towards the wild-type vessel is compared to the
hypermorph (Fig. 4B).
Isolation of vascular smooth muscle cells
Whole femoral and carotid arteries were harvested from six-week
old EYFP-transgelin mice. Vessels were washed two times in Hanks
balanced salt solution (HBSS, Invitrogen) and incubated for 10 min at
37 °C in 1mg/ml collagenase A (Sigma-Aldrich, St. Louis, MO) in HBSS.
The adventitia was removed from all vessels, which were then pooled
and washed twice in HBSS. Arteries were digested to single cell
suspensions by incubating in 2 mg/ml collagenase A, and 0.5 mg/ml
elastase (Sigma-Aldrich) for 30 min at 37 °C, triturating gently every
10min. Following inactivation of the enzymes by adding 2ml of media
(DMEM, 10% fetal bovine serum, 1% penicillin/streptomycin), dis-
sociated cells were collected by centrifugation at 1000 rpm for 10 min
at room temperature and then plated in 2.5 ml media in a 35 ml tissue
culture dish. Media was changed every three days and cells were split
after approximately four weeks. Eight weeks post-isolation, cells were
trypsinized and sorted by FACS to isolate only eYFP-positive femoral
and carotid smoothmuscle cells, which were then harvested to isolate
total RNA as described below.
Quantitative real-time PCR
For analysis of mRNA expression of VEGF-A, Sema3A and their
receptors inwhole vessels, femoral and carotid arteries were dissected
from postnatal day 2 mice and enzymatically digested (100 mg/ml
hyaluronidase, 200 mg/ml type II collagenase, and 10 µg/ml
proteinase K in DMEM) for 30 min at 37 °C. To obtain enough total
RNA for analysis, vessels from 8–10 animals were pooled. For analysis
of mRNA expression in isolated vascular smooth muscle cells, cells
isolated from 12 animals were pooled and collected immediately after
FACS sorting, as described above. RNA was extracted using Trizol
reagent (Invitrogen, Carlsbad, CA) and its integrity was assessed by an
Agilent Bioanalyzer (W.M. Keck Facility, Yale University) before being
reverse transcribed (iScript, Bio-Rad Laboratories, Inc., Hercules, CA).
Real time-PCR was carried out on an iCycler (Bio-Rad) using iQ SYBR-
Green Master mix in the presence of exon-spanning oligonucleotide
primers for VEGF-A and Sema3A (designed using PrimerQuest,
Integrated DNA Technologies, Coralville, IA, Fig. 3A) (Wang and
Seed, 2003). β-actin was used as an internal control to normalize
samples. The ampliﬁcation efﬁciencies of target (VEGF-A andSema3A) and reference (β-actin) genes were analyzed and found to
be equal. Melt curve analysis and ethidium bromide agarose gel
electrophoresis were performed to evaluate PCR products. Relative
quantiﬁcation of fold-change in mRNA expression was calculated
using the 2-DDCT method (Livak and Schmittgen, 2001). To calculate
femoral vs. carotid expression, carotid arteries were used as control
samples, and to calculate carotid vs. femoral expression femoral
arteries were used as controls.
PCR
Reverse Transcription-PCR was performed on femoral and carotid
cDNA using Clontech Advantage 2 PCR mix in the presence of exon-
spanning oligonucleotide primers for VEGFR2, Nrp1 and Plexin A1
(designed using PrimerQuest, Integrated DNA Technologies or from
Harvard Primer Bank [noted by Primer Bank ID numbers, Spandidos et
al., 2008; Wang and Seed, 2003]) (Fig. 3A) using a PTC-200 Thermal
Cycler (MJ Research, Waltham, MA). Following ampliﬁcation, PCR
products were analyzed using ethidium bromide agarose gel
electrophoresis.
Western blot
Femoral and carotid arteries were dissected from postnatal day 2
CD-1 mice, washed in PBS to remove blood, and homogenized in lysis
buffer (50mM Tris, pH 8.0, 150 mMNaCl, and 1% NP-40). Vessels were
pooled as described above. A bicinchoninic acid (BCA) assay (Thermo
Scientiﬁc, Rockford, IL) was used to measure protein concentration
and electrophoresis and membrane transfer was performed using
constant protein load as described previously (Li et al., 2007).
Membranes were blocked for 1 h (Tris-buffered saline/0.05% Tween
20 (TBST)/5% nonfat dry milk) and incubated overnight at 4 °C in
primary antibody solution (goat anti-mouse Sema3A, cat. # sc-1148;
rabbit anti-mouse VEGF-A, cat. # sc-507; Santa Cruz Biotechnology,
Santa Cruz, CA). β-actin (mouse anti-mouse, cat. # A5316 Sigma-
Aldrich, St. Louis, MO) was used as a normalizing protein. Membranes
were washed and incubated in the appropriate secondary antibody
(HRP-conjugated secondary antibodies, cat. # sc-2313 and sc-2314,
Santa Cruz Biotechnology) for 1 h at room temperature. Horseradish
peroxidase was detected with enhanced chemiluminescence (Pierce,
Rockland, IL) and captured on autoradiographic ﬁlm. Relative
intensities of bands representing proteins of interest were quantiﬁed
using Quantity One software (Bio-Rad Laboratories).
Immunostaining on isolated sympathetic neurons and whole SCG
explants
SCG were dissected from postnatal day 2 CD-1 mice and cleaned of
excess connective tissue, washed twice in sterile Hanks Balanced Salt
Solution (HBSS, Invitrogen) to remove any remaining media and
incubated in 0.025% trypsin for 30 min at 37 °C. SCG were washed
twice in media (DMEM/F12, 10% fetal bovine serum, 2 mM L-
glutamine, 2 mM penicillin/streptomycin, and 20 ng/ml NGF) to
inactivate the trypsin and then triturated gently with a glass Pasteur
pipette to dissociate the neurons. Dissociated cells were centrifuged
(200 g, 5 min) in a swinging bucket rotor (Sorvall, GLC-2B),
resuspended in fresh media and preplated on uncoated plastic tissue
culture plates for 1 h (5% CO2, 37 °C) before plating on pre-coated
(100 µg/ml poly-L-lysine, 10 µg/ml laminin) 8-well chamber slides
(cat. # 354108, BD Biosciences), and cultured for 16 h. Neurons were
ﬁxed in 4% PFA for 20 min at room temperature followed by blocking
and permeabilization in blocking buffer (4% normal goat serum, 0.1%
Triton-X in PBS) for 1 h at room temperature. Cells were then
incubated overnight at 4 °C in the appropriate primary antibody
diluted in blocking buffer (1:100 polyclonal rabbit anti-human
VEGFR2, cat. # 2479, Cell Signaling Technology, Danvers, MA;
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Cambridge, MA; polyclonal rabbit anti-human Flt1, cat. # sc-9029,
and polyclonal rabbit anti-human neuropilin, cat. # sc-5541, Santa
Cruz). Neurons werewashed three times in PBS and then incubated in
secondary antibody for 1 h at room temperature (1:100 Alexa Fluor
488 goat anti-rabbit, cat. # A11008, Invitrogen). Following another PBS
wash, coverslips were mounted with Vectashield containing DAPI
(Vector Labs, Burlingame, CA). Neurons were then visualized using an
inverted microscope (IX71-SIF; Olympus, Center Valley, PA) with
LCplanFL 20×NA 0.40 objective (Olympus) and capturedwith a digital
camera (S97809; Olympus) using Picture Frame acquisition software
(Optronics).
Whole P2 explants were dissected as described previously and
cultured in the presence of femoral and carotid artery segments in
2.5 mg/ml collagen gel for 16 h. Ganglia were ﬁxed in 4% PFA for
20 min at room temperature and washed three times in 1× PBS. Co-
cultures were incubated in blocking buffer (4% normal goat serum,
0.1% Triton-X in PBS) for 2 h at room temperature and then in primary
antibody (1:100 polyclonal rabbit anti-human VEGFR2, polyclonal
rabbit anti-human PlexinA1, polyclonal rabbit anti-human Flt1,
polyclonal rabbit anti-human neuropilin) diluted in blocking buffer
overnight at 4 °C. Vessels were washed six times for 1 h at 4 °C inwash
buffer (1% normal goat serum, 0.1% Triton-X in PBS) and incubated in
goat anti-rabbit Alexa Fluor 488. Following six one-hour washes at
4 °C in wash buffer, co-cultures were imaged using a confocal
microscope (Fluoview 200 Olympus, Center Valley, PA) with UPlanFl
10× NA 0.30 objective (Olympus).
SCG/VEGF-A and SCG/Sema3A sphere co-culture
Alginate spheres entrapping rhVEGF-A or rhSema3A/Fc were
formed via an external gelation process. For all spheres, a 1% alginate
(LVG, FMC Biopolymer, Philadelphia, PA) solution containing various
concentrations of (0–10% w/v) rhVEGF-A165 or rhSema3A/Fc
(Sema3A/Fc, R&D Systems, Minneapolis, MN) was added drop wise
into an aqueous solution of 100 mM SrCl2 through a 30-gauge needle
to produce spheres approximately 1 mm in diameter. Spheres were
allowed to cure for 10 min in solution, washed in dH2O, snap frozen in
liquid nitrogen and lyophilized. To determine the release proﬁle
(VEGF-A) or activity (Sema3A/Fc), spheres were embedded in 150 μl
type I collagen gel in 1 ml co-culture medium and incubated at 37 °C.
Media were removed at each time-point (1, 2, 4, 8, 12, 16 h) and
replaced with fresh media. VEGF-A concentration in media samples
was determined by ELISA (DuoSet, R&D Systems, Minneapolis, MN).
Sema3A/Fc activitywas assayed as described previously (Schwamborn
et al., 2004). Brieﬂy, 2×104 PC12 cells were seeded onto ﬁbronectin
coated coverslips in a 24-well plate and cultured for 24 h in PC12media
(DMEM, 10% heat-inactivated horse serum, 5% fetal bovine serum,
1% penicillin/streptomycin). Cells were then incubated in 16 h
Sema3a/Fc conditioned media for 12 h, ﬁxed with 4% PFA and stained
with FITC-phalloidin to visualize neurites and growth cones. 50 ng/ml
NGF was used as a positive control and blank sphere conditioned
media served as a negative control. The percentage of cells extending
neurites was counted and expressed as a percent of total cells.
For co-culture experiments, single alginate spheres were
embedded in type I collagen gel 2 mm from postnatal day 2 SCG.
Cultures were ﬁxed after 16 h and co-cultures were analyzed as
described above. For SCG/sphere co-cultures, measurements repre-
sent sphere/non-sphere directed neurite outgrowth. To block VEGF-A
released from spheres, blocking antibodies directed towards human
recombinant VEGF-A (clone JH121, cat. # 05-443, Millipore, Billerica,
MA) or a highly speciﬁc VEGFR2 inhibitor (VEGR2 Kinase Inhibitor I,
Calbiochem, San Diego, CA; Sun et al., 1988) were added to the media
in indicated concentrations. Three independent experiments were
performed with four or ﬁve SCG explants used per treatment in each
(total n=12–14).Vascular innervation co-cultures
Postnatal day 2 SCG were cultured in the presence of either adult
femoral or carotid segments as described above for SCG explant co-
cultures but were cultured for 5 days. Neurovascular co-cultures were
immunostained as described above for whole SCG explants (rabbit
anti-mouse tyrosine hydroxylase; goat anti-rabbit Alexa Fluor 488).
Co-cultures were imaged using a confocal microscope (Fluoview 200
Olympus, Center Valley, PA) with UPlanFl 10× NA 0.30 objective
(Olympus).
Statistics
The data were analyzed by ANOVA (StatView, SAS Institute Inc.,
Cary, NC) and reported as the mean±standard error. Statistical
signiﬁcance was assumed when pb0.05.
Results
In rodents, post-synaptic sympathetic nerves densely innervate
femoral, while the carotid artery can be considered sparsely
innervated. To verify the vascular cell type innervated by sympathetic
nerves, femoral and carotid artery segments were sectioned and
stained with tyrosine hydroxylase (TH) to visualize axons, platelet
endothelial cell adhesion molecule-1 (PECAM-1) to localize endothe-
lial cells (EC) and smooth muscle alpha actin (SMAA) to visualize
smooth muscle cells (SMC). In femoral segments, signiﬁcant TH
immunoﬂuorescence was visible representing sympathetic innerva-
tion (Figs. 1A, B, D, E, G, H). Double-labeling with PECAM-1 and SMAA
revealed that sympathetic varicosities are localized to the medio-
adventitial border, closely approaching the SMC layer while failing to
make contact with EC (TH/PECAM Figs. 1A–B, TH/SMAA Figs. 1D, E).
Carotid arteries were devoid of TH ﬂuorescence (Figs. 1C, F, I). To
determine whether sympathetic nerves form synaptic contacts
(varicosities) with vessels or simply travel along the vessel towards
more distal targets, double-labeling was performed using TH and
synaptophysin, a non-speciﬁc synaptic marker. Signiﬁcant synapto-
physin immunoﬂuorescence was present at the medio-adventitial
border of both the carotid and femoral arteries; however only in
femoral artery segments were synapses co-labeled for TH and
synaptophysin (Figs. 1G, H). While sympathetic innervation is absent
from carotid artery sections (Figs. 1C, F, I), both carotid and femoral
artery sections showed signiﬁcant cholinergic innervation that co-
localizes with synaptophysin (Figs. 1J, K).
To evaluate the changes in the density of femoral artery
innervation during the early postnatal period, TH immunoﬂuores-
cence and calculation of innervation density were performed on
whole mount vessels between postnatal days 0 and 9 as well as adult
vessels. Innervation densities were signiﬁcantly different from adult
(0.07±0.006) between postnatal days 0 through 3 (0.037±0.001
through 0.057±0.002), after which there were no signiﬁcant
differences (Fig. 1L).
To determine whether differences in neurite outgrowth towards
innervated (femoral arteries) and non-innervated (carotid arteries)
vessels exist, a 3D co-culture systemwas used to quantify sympathetic
axon length towards femoral and carotid artery segments. SCG
explants from P2 mice and artery segments from adult mice were
embedded in a type I collagen gel (Fig. 2A). Fig. 2B illustrates the TH
positive baseline sympathetic neurite outgrowth from the SCG. When
SCG were cultured alone, there was radial outgrowth around the
entire SCG (data not shown). In single vessel co-cultures, when
carotid artery segments alone were cultured with SCG explants,
average neurite length decreased towards the vessel segment
compared to that on the contralateral side (20±5%, n=14, data not
shown) and when femoral artery segments alone were co-cultured
with SCG explants, there was an increased vessel directed neurite
Fig. 1. Localization of murine vascular sympathetic innervation. (A–C) Immunolabeling for PECAM-1 (green) to mark vascular endothelial cells, tyrosine hydroxylase (red) to mark
sympathetic nerves and DAPI (blue) to mark nuclei in femoral (A, B=boxed area in panel A) and carotid arteries (C). Localization of both tyrosine hydroxylase and PECAM-1 is found
in adult femoral artery sections (A and B, arrows) but tyrosine hydroxylase localization is absent from adult carotid artery sections (C). L=lumen. Scale bar=50 μm. (D–F)
Immunolabeling for smoothmuscle cell actin (red) tomark vascular SMCs, tyrosine hydroxylase (green) and DAPI (blue) tomark nuclei in femoral (D, E=boxed area in panel D) and
carotid arteries (F). Innervation patterns match that of PECAM-1/TH double-labeling (D and E, arrows). Sympathetic nerves are localized to the medio-adventitial border of the
femoral arteries (orange–yellow ﬂuorescence — arrows). Scale bar=50 μm. (G–I) Immunolabeling for synaptophysin (red) to mark synapses, tyrosine hydroxylase (green) to mark
sympathetic nerves and DAPI (blue) to mark nuclei in femoral (G, H=boxed area in panel G) and carotid (I) artery sections. Both vessels show signiﬁcant synapse formation around
the periphery, but synapses with sympathetic nerves are localized only in femoral artery sections (G and H, orange–yellow ﬂuorescence — arrows). Scale bar=50 μm. (J and K)
Immunolabeling for synaptophysin (red) to mark synapses, vesicular acetylcholine transferase (green) to mark sympathetic nerves and DAPI (blue) to mark nuclei in femoral (J) and
carotid (K) artery sections. Both vessels show signiﬁcant synapse formation around the periphery (orange–yellow ﬂuorescence — arrows). Scale bar=50 μm. (L) Innervation
densities were quantiﬁed in femoral arteries from postnatal days 0 through 9mice by whole mount tyrosine hydroxylase immunoﬂuorescence. Innervation density was calculated as
described in Materials and methods and represents total nerve length (μm)/surface area (μm2) for the superﬁcial half of each vessel. Signiﬁcant differences between postnatal and
adult innervation differences exist between days 0–3, after which no differences exist. Carotid arteries are not innervated (data not shown) (n=6; vertical bars represent standard
error; ⁎=pb0.05).
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used in a single co-culture, average neurite outgrowth towards the
femoral artery was higher than carotid directed outgrowth (19±5%)
(Figs. 2C, D). Preliminary neurovascular co-cultures performed using
P2 vessels and SCG showed similar results (15±4%, n=8, data not
shown). Due to the fragility and size of P2 vessels, adult vessels were
used in subsequent experiments because they are larger and easier to
manage. In addition, following local freeze-damage, sympathetic
reinnervation of adult begins within two weeks, suggesting that these
vessels upregulate the expression of axon growth promoting guidance
cues (Looft-Wilson et al., 2004). To evaluate whether the presence of
the carotid or femoral artery is sufﬁcient to disrupt the expected
pattern of neurite outgrowth rearrangements of the vessels in the 3D
co-culture were used (Fig. 2D). First we placed femoral arteries on the
same side of the SCG as the carotid artery, either proximal (CFSF; C =
carotid, F = femoral, S = SCG) or distal to the SCG (FCSF). No
signiﬁcant difference was observed in directed neurite outgrowth
compared to that observed towards the carotid artery segment in the
3D co-culture (Fig. 2D). In contrast, the placement of carotid artery
segments on the same side as the femoral artery either proximal
(FCSC) or distal (CFSC) to the SCG blunted the femoral artery
mediated neurite outgrowth (Fig. 2D).
As both VEGF-A and Sema3A have been implicated in neuronal
survival, proliferation and axon outgrowth via interactions with
neuropilin-1 and VEGFRs, we tested their ability to inﬂuence SCG
outgrowth. First, we evaluated the expression of both growth factors
and their receptors by quantitative real-time PCR (qRT-PCR) to
measure mRNA levels and Western blot to determine protein
expression in both whole vessel and isolated smooth muscle cells
(SMC). In both whole femoral arteries, VEGF-A mRNA expression wasthree-fold higher compared to the carotid artery. In contrast, Sema3A
mRNA showed an opposite trend of the same magnitude (Fig. 3B). In
isolated SMC, VEGF-A mRNA expression was approximately 1.5-fold
higher in femoral SMC compared to carotid SMC, while Sema3AmRNA
was three-fold higher in carotid compared to femoral SMC (Fig. 3B).
Analysis of mRNA levels revealed that Nrp-1, Plexin A1 and VEGFR2
are present in SCG explants as well as in vessels (Fig. 3C). To evaluate
whether the presence of vessels elicited a change in localization of
these receptors SCG, whole explants were co-cultured alone or with
femoral and carotid artery segments and immunoﬂuorescent staining
was performed for Nrp-1, PlexinA1, VEGFR2 and VEGFR1. There were
no changes in localization of these receptors between SCG cultured
alone and SCG co-cultured with innervated and non-innervated vessel
segments (Supplementary Figure 4). To ensure that the expression of
these receptors was speciﬁc to sympathetic neurons and not the result
of capillaries in the SCG, immunoﬂuorescent staining was performed
on dissociated SCG neurons (Fig. 3D). All four receptors were
expressed in dissociated sympathetic neurons. VEGFR2, PlexinA1
and Nrp-1 appeared to be localized throughout the neuron while
VEGFR1 appeared to be restricted primarily to the cell body, although
faint immunoﬂuorescence was observed along the axon (Fig. 3D).
Despite the signiﬁcant difference in VEGF-A mRNA expression in
femoral vs. carotid, there were no signiﬁcant differences in VEGF-A
protein expression inwhole vessels. However, Sema3A expressionwas
signiﬁcantly higher in the carotid artery compared to the femoral
artery whole vessel lysates (Figs. 3E, F).
Next we explored the role of vascular-derived VEGF-A in promot-
ing sympathetic neurite outgrowth. VEGF-A (hi/+) mice exhibit
subtle but signiﬁcant increases in femoral artery sympathetic
innervation density compared to wild-type littermates both as adults
Fig. 2. Directed migration in neurovascular co-cultures. (A) Schematic representing three-dimensional in-vitro co-culture. Whole SCG explants from postnatal day 2 mice were co-
cultured in the presence of adult femoral and carotid artery segments. Tissues were embedded in type I collagen gel 2 mm apart and cultured for 16 h. (B) Tyrosine hydroxylase
immunolabeling in whole SCG explants. Left, low magniﬁcation; right (boxed inset), high magniﬁcation. Scale bar=100 μm. (C) Representative image of SCG co-cultured with
femoral and carotid artery segments. Femoral and carotid artery segments were placed 2mm from SCG explants. To quantify outgrowth, the area occupied by the SCG and its neurites
was divided into quadrants (solid lines). Average axon length was measured for 25 axons in the femoral and carotid directed quadrants (outlined by dashed lines). Carotid directed
average axon length was normalized to 1 and femoral/carotid ratios were calculated. Scale bar=100 μm. (D) Directed neurite outgrowth of sympathetic axons from whole SCG
explants. Neurites of equal average length grew radially from SCG alone controls (data not shown). In femoral/carotid co-cultures (ﬁrst pair of bars) (FSC) the average axon length
was signiﬁcantly increased towards the femoral compared to the carotid artery. (n=14; ⁎=pb0.05; vertical bars represent standard error.) To test the effect of vessel
rearrangements on directed neurite outgrowth, SCG explants (S) were cultured in the presence of various arrangements of vessels. When femoral segments (F) were placed on the
same side as carotid segments (C), either proximal (second pair of bars) (FSCF) or distal to the SCG (S) (third pair of bars) (CSFC) outgrowth towards the femoral segment was
blunted, with the placement of carotid segments disrupting the typical increased outgrowth observed towards femoral segments. (n=14; ⁎=pb0.05; vertical bars represent
standard error.) When femoral segments (F) were placed on the same side as carotid segments (C), either distal (fourth pair of bars) (CSCF) or proximal to the SCG (S) (ﬁfth pair of
bars) (FSFC) outgrowth towards the carotid segment was unchanged.
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density/μm (Fig. 4A) and by counting the number of tyrosine
hydroxylase positive puncta (Fig. 4B). In both wild-type and VEGF-A
(hi/+) littermates, the common carotid is not innervated by
sympathetic nerves. Co-culture experiments using wild-type SCG
and vessel segments from wild-type mice and mice exhibiting high
(VEGF-A (hi/+) VEGF-A expression (Miquerol et al., 1999, Miquerol et
al., 2000) were used to further evaluate the role of VEGF-A in
modulating vascular sympathetic outgrowth (Fig. 4C). Both femoral
and carotid arteries express approximately 40% higher levels of VEGF-
A mRNA and protein compared to wild-type littermates (Supplemen-
tary Figure 1). Because femoral arteries express little Sema3A (Figs.
3E–F), Sema3A expression levels in VEGF-A (hi/+) carotid vessels
were evaluated and were found to be no different from wild-type
littermates (Supplementary Figure 1). Vessels harvested from wild-
type littermates displayed no deviation from the expected patterns of
outgrowth with increased average axon length towards the femoral
compared to the carotid artery (18±4%, n=12) (Fig. 4C, second pair
of bars, WF-S-WC). This also occurred when VEGF-A (hi/+) femoral
artery segments were used (20±5%, n=12) (Fig. 4C, third pair of
bars, VF-S-WC). However, when VEGF-A (hi/+) carotid artery
segments were used in co-culture with wild-type femoral segments,
the pattern of outgrowth was reversed. Average axon length was
increased towards the VEGF-A (hi/+) carotid artery compared to the
femoral artery (13±4%, n=12) (Fig. 4C, fourth pair of bars, WF-S-
VC). When both femoral and carotid segments were from VEGF-A (hi/
+) mice, there was no signiﬁcant difference in outgrowth towards
either vessel (Fig. 4C, ﬁrst pair of bars, VF-S-VC). Co-cultures were
performed with either carotid or femoral arteries from wild-type and
VEGF-A (hi/+) littermates. In both carotid–carotid and femoral–femoral vessel co-cultures, outgrowth towards the VEGF-A (hi/+)
was signiﬁcantly higher than towards the wild-type vessel (Fig. 4C,
ﬁfth and sixth pairs of bars, WC-S-VC, WF-S-VF). The effect of
increased VEGF-A was more signiﬁcant in carotid vs. femoral cultures
(15±4%, 8±2%) suggesting that VEGF-A may provoke a larger
outgrowth response in carotid arteries. To block VEGF-A released from
vessels, VEGF-A blocking antibodies were included in VEGF-A (hi/+)
co-cultures. In WF-S-WC, VF-S-WC and WF-S-VC co-cultures, inclu-
sion of the blocking antibody was able to blunt the increase in
outgrowth observed towards one vessel compared to the other
(Supplementary Figure 2). In VF-S-VC co-cultures, the antibody
restored the increased outgrowth observed towards the femoral
artery observed in wild-type neurovascular co-cultures.
Additionally, we evaluated the effect of increased exogenous
rhVEGF-A on SCG explants. Single alginate spheres loaded with
known amounts (w/v) of human recombinant VEGF-A were used in
co-culture with SCG explants to evaluate directed axon outgrowth
towards known VEGF-A gradients. Mouse and human VEGF-A share
approximately 90% homology and human VEGF-A has been used in
previous studies using mouse cells (Smith et al., 2004). Quantitative
VEGF-A release proﬁles of VEGF-A/alginate spheres containing
various w/v percentages of VEGF-A (0.6%, 1.25%, 2.5%, 5% and 10%)
were observed to exhibit reproducible, quantiﬁable release proﬁles
into media over the 16 h time frame of the co-culture experiments
(0 ng/ml, 1.2±0.2 ng/ml, 16.9±2.8 ng/ml, 26.0±4.4 ng/ml, and
67.0±14.0 ng/ml respectively; Fig. 4C). Release proﬁles were also
performed for VEGF-A spheres embedded in 2.5 mg/ml collagen gel,
which produced similar trends for release, although the magnitude
of release into the media was decreased compared to media alone.
This is likely caused by association of VEGF-A molecules with the
Fig. 3. Expression of guidance cues and their receptors in vessels and SCG. (A) VEGF-A, Sema3A, VEGFR2, Nrp1 and PlexinA1 forward and reverse primer sets used for quantitative
real-time PCR and RT-PCR. (B) Quantitative real-time PCR analysis of VEGF-A and Sema3A in femoral and carotid artery isolated smooth muscle cells (SMC) and whole vessels.
Femoral arteries and SMC express a three-fold increase in VEGF-A mRNA compared to carotid arteries and SMC while the expression proﬁle of Sema3A in the reciprocal. (n=3 for
each gene of interest; ⁎=pb0.05; vertical bars represent standard error.) (C) RT-PCR analysis of receptor expression in vessels and SCG. Femoral and carotid arteries as well as SCG
expressmRNA for VEGFR2, Nrp1 and PlexinA1. (D) Immunoﬂuorescent analysis of VEGFR1, VEGFR2, PlexinA1 and Nrp1 in postnatal day 2 dissociated SCG neurons. Scale bar=50 μm.
(E) Protein expression of guidance cues in postnatal day 2 whole vessel lysates. Representative Western blots of femoral (F) and carotid (C) artery segments identifying Sema3A and
VEGF-A normalized to beta actin. (F) Quantiﬁcation of Western blot data. Sema3A expression is signiﬁcantly higher in carotid compared to femoral artery segments while VEGF-A
expression is not signiﬁcantly different between vessels (n=3 for each gene of interest; ⁎=pb0.05; vertical bars represent standard error).
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In co-culture with SCG explants, there was no signiﬁcant difference
in average axon length towards empty spheres or towards 0.6% w/v
VEGF-A spheres (Fig. 4E.) Increases in outgrowth towards VEGF-A
containing spheres were dose-dependent with the highest increase
in outgrowth towards spheres containing 2.5% w/v VEGF-A (25±7%
higher than towards empty spheres, Fig. 4E). In addition, there were
no signiﬁcant differences in axon length towards the 5% and 10%
spheres compared to that towards blank spheres (Fig. 4E). To
determine whether these effects were due speciﬁcally to VEGF-A,
human VEGF-A neutralizing antibodies were used to sequester
exogenous VEGF-A that diffused from the alginate spheres into the
collagen gel in SCG alone cultures. Concentrations as low as 500 ng/
ml of neutralizing antibody were able to block the outgrowth-promoting effect of 2.5% VEGF-A spheres in SCG co-cultures (Fig. 5A,
axon length normalized to no-antibody control). When lower
concentrations of VEGF-A neutralizing antibody were used (100
and 250 ng/ml) there was no effect of the antibody on expected
neurite outgrowth compared to 2.5% VEGF-A sphere controls
without antibody. In addition, a highly selective cell permeable
VEGFR2 tyrosine kinase inhibitor (Sun et al., 1988) was able to
similarly block the increased average axon length towards 2.5%
VEGF-A spheres at concentrations as low as 1 μM (Fig. 5B, axon
length normalized to no inhibitor control). To evaluate whether the
growth promoting effect of femoral arteries may be attributed to
VEGF-A signaling SCG–femoral co-cultures were performed using
various concentrations of VEGFR2 inhibitor (Fig. 5C, vessel and non-
vessel average axon length at all concentrations of inhibitor was
Fig. 4. The effect of VEGF-A on directed neurite outgrowth (unless otherwise noted n=14, vertical bars represent standard error). (A, B) Innervation analysis of sympathetic
innervation in VEGF-A (hi/+) compared to wild-type littermates. Tyrosine hydroxylase immunostaining revealed signiﬁcant increases in sympathetic innervation density measured
by both immunoﬂuorescence intensity (A) and # of TH positive puncta (B) in both adult and postnatal day 16 compared to matched WT controls. (n=5 for each age group;
⁎=pb0.05, ⁎⁎=pb0.01.) (C) Neurovascular co-cultures using vessels from VEGF-A (hi/+) heterozygous mice and wild-type littermates. When placed on either side of SCG, VEGF-A
(hi/+) carotid and femoral artery segments elicited an increased equal neurite outgrowth compared to wild-type carotid segments, reﬂecting increased VEGF-A expression in both
vessel segments (ﬁrst pair of bars), in contrast to the differential neurite outgrowth towards femoral artery segments observed when wild-type vessel segments were used (second
pair of bars). Similar outgrowthwas noted when VEGF-A (hi/+) femoral artery segments (VF) were compared towild-type carotid artery segments (WC) (third pair of bars). VEGF-A
(hi/+) carotid artery segments (VC) promoted increased average axon length from the SCG (S) when cultured with both wild-type femoral (WF) (fourth pair of bars) and wild-type
carotid (WC) (ﬁfth pair of bars) vessel segments. Lastly, VEGF-A (hi/+) (VF) femoral segments elicited increased outgrowth compared to wild-type femoral artery segments (WF)
(sixth pair of bars). Interestingly, femoral artery segments from VEGF-A (hi/+) (VF) mice did not promote further increases in expected average axon length when cultured with
wild-type carotid artery segments (WC) than did wild-type femoral artery segments (WF) (compare the second and third pairs of bars). (⁎=pb0.05.) (D) Release of VEGF-A into
type I collagen gel from VEGF-A/alginate spheres by ELISA. VEGF-A/alginate spheres released increasing amounts of VEGF-A into the media over 16 h. Amounts of VEGF-A released
ranged from 70 ng/ml (10% w/v VEGF-A) to 1.5 ng/ml (1.25% and 0.625% w/v VEGF-A, inset). (E) SCG outgrowth in response to VEGF-A/alginate spheres. Average sympathetic
neurite lengths towards 2.5% and 1.25% w/v VEGF-A/alginate spheres was approximately 25% and 18% higher respectively compared to the non-vessel quadrant. Control, 0.625%, 5%
and 10% w/v spheres caused no signiﬁcant increases in outgrowth. (⁎=pb0.05.)
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co-cultures, the VEGFR2 inhibitor was able to decrease overall
neurite outgrowth towards both the vessel and non-vessel directions
in a dose-dependent manner using concentrations as low as 1 μM.However, when average outgrowth towards the non-vessel direction
was normalized to vessel-directed (femoral) outgrowth, at all
concentrations of VEGFR2 inhibitor there was still an increased
outgrowth towards the artery (Fig. 5D, non-vessel-directed axon
Fig. 5. The effect of VEGF-A neutralization on directed neurite outgrowth (n=14, vertical bars represent standard error). (A) The effect of VEGF-A neutralizing antibodies on average
axon length. Anti-human VEGF-A antibodies were used to neutralize the effect of VEGF-A released from alginate spheres. Concentrations as low as 500 μg/ml were able to block the
effect of the VEGF-A/alginate spheres compared to sphere alone controls. (⁎=pb0.05.) (B) The effect of a VEGFR2 inhibitor on average axon length. A highly speciﬁc cell permeable
VEGFR2 tyrosine kinase inhibitor was used to block signaling from VEGF-A released from alginate spheres. Concentrations as low as 1 μg/ml were able to block the effect of VEGF-A/
alginate spheres compared to sphere alone controls (ﬁrst bar on the left). (C) The effect of the VEGFR2 inhibitor on femoral–SCG neurovascular co-cultures. The cell permeable VEGFR2
inhibitorwas also able to decrease neurite outgrowth elicited by femoral artery segments co-culturedwith SCG. (⁎=pb0.05.) Average axon length (for vessel and non-vessel cultures)
at all inhibitor concentrations is normalized to axon lengths with no VEGFR2 inhibitors. On both the vessel and non-vessel sides of the SCG, there is a decreased average axon length
compared to the no inhibitor control (ﬁrst pair of bars on the left). (D) The effect of VEGFR2 inhibitors on the increase in axon outgrowth elicited by femoral artery segments. At each
concentration of VEGFR2 inhibitor, average axon length on the non-vessel side of the SCG is normalized to the average axon length towards the vessel. AlthoughVEGFR2 tyrosine kinase
inhibitors were able to signiﬁcantly decrease overall axon length in femoral–SCG neurovascular co-cultures at all inhibitor concentrations tested, the ratio of vessel/non-vessel
outgrowth was maintained with signiﬁcantly more outgrowth observed in the quadrant towards the femoral artery segment compared to the non-vessel quadrant. (⁎=pb0.05.)
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concentration).
To evaluate the effect of other VEGF-A receptors in directed neurite
outgrowth, VEGFR1 and Nrp1 function-blocking antibodies were used
in SCG alone and neurovascular co-cultures. VEGFR1 antibodies had
no effect SCG cultures (Supplementary Figure 3A) or on the overall
average axon length in femoral–SCG co-cultures at all concentrations
tested (Supplementary Figure 3B; vessel and non-vessel average axon
length at all concentrations of inhibitor was normalized to no inhibitor
control). In addition, when average outgrowth towards the non-vessel
direction was normalized to vessel-directed (femoral) outgrowth,
VEGFR1 antibodies were also unable to alter the expected pattern of
outgrowth and there was an increased average axon length towards
the vessel (Fig. 3C; non-vessel-directed axon length normalized to
vessel directed axon length at each inhibitor concentration).
Similar co-culture experiments to those conducted with VEGF-A
were performed to evaluate the effects of Sema3A in promoting or
repressing sympathetic neurite outgrowth. Alginate spheres encap-
sulating known amounts (0%, 1.25%, 2.5% and 5% w/v) of
recombinant chimeric human Sema3A/Fc were used in co-culture
with SCG explants to evaluate directed axon outgrowth towards
gradients of Sema3A. As with VEGF-A, mouse and human Sema3A
share a high degree of homology and Sema3A/Fc has been used in-
vitro with mouse neural crest cells (Xu et al., 2006). Due to the lackof reagents of required sensitivity, it was not possible to determine
the exact release proﬁle of Sema3A from alginate spheres. However,
we conducted neurite outgrowth assays using PC12 cells in the
presence of Sema3A/alginate sphere conditioned media. Our results
suggested that as Sema3A increased, the percentage of PC12 cells
that produced neurites increased (data not shown). In co-culture
with SCG explants, average axon length towards Sema3A containing
alginate spheres decreased in a dose-dependent manner compared
to axon length towards empty spheres. Average axon length towards
the 1.25% w/v and 2.5% w/v Sema3A/Fc spheres was decreased by
approximately 14±3% and 16±3% respectively compared to out-
growth towards blank spheres in the same well (Fig. 6A). As with
the VEGF-A encapsulated spheres, there were no signiﬁcant
differences in axon length towards the 5% w/v spheres compared
to that towards the blank spheres (Fig. 6A). Due to the limited
availability of speciﬁc Sema3A inhibitors/antagonists that do not act
by blocking Nrp1 signaling, it was not possible to evaluate their
effects on neurite outgrowth.
To evaluate if either growth factor signaling pathway predomi-
nates in our in-vitro co-culture, SCG cultures were performed in
the presence of both VEGF-A and Sema3A/Fc-encapsulated alginate
spheres, either on opposing sides of the SCG or in combination on
the same side. First, experiments were conducted with alginate
spheres on opposing sides of the SCG. When 2.5% w/v VEGF and
Fig. 6. The effect of Sema3A on directed neurite outgrowth (n=14, vertical bars represent standard error). (A) SCG outgrowth in response to Sema3A/alginate spheres. An average
sympathetic neurite length towards 1.25% and 2.5% Sema3A/alginate spheres was decreased by approximately 25% compared to empty spheres. 5% Sema3A/alginate spheres caused
no signiﬁcant decrease in neurite outgrowth. (⁎⁎=pb0.01.) (B, C) SCG outgrowth in response to VEGF-A/alginate and Sema3A/alginate spheres placed on opposite sites of the SCG.
Average neurite outgrowth towards VEGF-A spheres was 17% higher compared to empty spheres and was decreased by 21% towards Sema3A spheres compared to empty spheres.
There were no signiﬁcant differences when VEGF-A and Sema3A spheres were used in combination in dual sphere cultures compared to single sphere cultures at either 2.5% (B) or
1.25% (C) VEGF and Sema3A. (⁎⁎=pb0.001.) (D) SCG outgrowth in response to VEGF-A/Sema3A/Blank alginate spheres. Alginate spheres were placed in combination on the same
side of the SCG. Neurite outgrowth towards VEGF-A/Blank spheres was 16.5% higher and towards the Sem3A/Blank spheres was 14% lower compared to the non-sphere side. When
2.5% VEGF-A and a 5% Sema3A spheres were used, there was only a 6% increase in outgrowth towards the spheres compared to the non-sphere side. When 5% VEGF-A and 2.5%
Sema3A spheres were used, there was an 18% decrease in outgrowth compared to the non-sphere side. (⁎=pb0.05.)
128 J.B. Long et al. / Developmental Biology 334 (2009) 119–132Sema3A alginate spheres were used in co-culture with SCG,
outgrowth patterns were similar to those seen in single sphere
co-cultures with approximately 22±5% increased growth towards
the VEGF-A containing sphere compared to the Sema3A sphere
(Fig. 6B). Similar patterns of outgrowth were seen when 1.25% w/v
spheres were used, although the magnitude of the difference was
decreased (13±4% increased outgrowth towards the VEGF-A
sphere) which is similar to the decrease in outgrowth observed
when 1.25% w/v spheres were used in single sphere co-cultures
(Fig. 6C). Since co-culture experiments utilizing equal concentra-
tions of spheres produced similar results to individual sphere
experiments, co-cultures were performed that included varied
concentrations of VEGF-A and Sema3A/Fc spheres. We evaluated
the effect of VEGF-A and Sema3A spheres on neurite outgrowth
when the spheres were both placed on the same side of the SCG,
creating a combinatorial effect of their concentration gradients.
Again, we used VEGF-A/Blank and Sema3A/Blank cultures as
controls and results were not signiﬁcantly different from our
original alginate sphere studies (Figs. 4D, 6A–C). When 2.5% w/v
Sema3A and blank spheres were used on the same side of the SCG,
there was a decrease in outgrowth own the sphere side of the SCG
of approximately 14±5% (Fig. 6D, second pair of bars). When 2.5%
VEGF-A and blank spheres were placed on the same side of theSCG, there was an approximately 16±3%, increase in growth
towards the spheres (Fig. 6D, third pair of bars). Both of these
results are consistent with earlier single sphere outgrowth data.
When 2.5% VEGF-A and 5% Sema3A spheres were placed on the
same side of the SCG, there was not a signiﬁcant increase in
outgrowth towards the spheres compared to the non-sphere side of
the SCG (Fig. 6D, fourth pair of bars). In contrast, when 5% VEGF-A
and 2.5% Sema3A spheres were used, there was an approximately
18±6% decrease in outgrowth towards the spheres compared to
the non-sphere side of the SCG (Fig. 6D, ﬁfth pair of bars). Our
observation that the 2.5% VEGF/5% Sema3A combination did not
elicit an inhibition of outgrowth is consistent with our previous
data in which this concentration of Sema3A was noted not to affect
outgrowth in single sphere co-cultures.
To conﬁrm the role of Nrp1 signaling in regulating sympathetic
neurite outgrowth, function-blocking Nrp1 antibodies were used in
both SCG alone and SCG–vessel neurovascular co-cultures. In SCG
alone cultures, concentrations as low as 500 ng/ml of Nrp1 antibody
were able to decrease average axon length compared to control
(Supplementary Figure 3D). To determine whether vascular-derived
Nrp1 ligands are responsible for regulating patterns of sympathetic
axon outgrowth in-vitro, femoral–SCG–carotid co-cultures were
performed. At concentrations of 1 μg/ml and higher, Nrp1 antibodies
129J.B. Long et al. / Developmental Biology 334 (2009) 119–132eliminated the increased outgrowth observed towards the femoral
artery compared to the carotid (Supplementary Figure 3E). To
determine whether VEGF-A/Nrp1 signaling mediated this effect,
femoral–SCG single vessel cultures, concentrations of 1 μg/ml or
higher were able to block the growth promoting effects of the femoral
artery (data not shown). To determine whether Sema3A/Nrp1
signaling mediated the decrease in outgrowth towards carotid
arteries, SCG–carotid co-cultures were performed and concentrations
of 10 μg/ml or higher were able to block the growth inhibitory effects
of the carotid artery (data not shown).
Finally, as neurite outgrowth and target innervation are
inherently different processes, femoral and carotid arteries were
co-cultured with whole SCG explants for ﬁve days to allow neurites
to extend out to/past the vessel segments. Using phase microscopy,
it appeared that neurites approached both vessels but only grew
past the artery segment in carotid–SCG co-cultures (Fig. 7B). In
femoral–SCG co-cultures, neurites grew to the vessel and did not
appear to grow past the vessel segment (Fig. 7A). Using confocal
microscopy, we imaged both neurovascular co-cultures to evaluate
whether vessels were innervated by sympathetic axons following
ﬁve days in culture. In carotid–SCG co-culture, tyrosine hydroxylase
axons appeared to grow across the vessel as well as underneath but
not wrap intimately around the vessel (Fig. 7D). In contrast, in
femoral–SCG co-cultures, tyrosine hydroxylase positive axons
wrapped extensively around the vessel and formed a dense
meshwork of axons around the vessel, similar to what we observed
in-vivo (Fig. 7C).
Additionally, when femoral–SCG co-cultures were double-labeled
with anti tyrosine hydroxylase and synaptophysin, co-localization of a
fraction of the synaptic varicosities was noted, consistent with
sympathetic re-innervation (Figs. 7E, G). In contrast, in cultures of
femoral artery segments alone, while synaptophysin puncta were stillFig. 7. Five-day neurovascular co-culture. (A, B) Fluorescent images of tyrosine hydroxylase
days in co-culture. In femoral–SCG co-cultures axons grew out to, but did not pass the vesse
around the vessel, forming a network parallel and perpendicular to the axis of the vesse
bar=200 μm. (C, D) Confocal images of tyrosine hydroxylase immunoﬂuorescence of SCG ex
ml collagen. Neurons comprising the femoral network were arranged both parallel and perp
network were arranged mainly perpendicular to the vessel axis with occasional axons mig
Merged images of a ﬁve-day co-culture of a femoral artery segment with a SCG (E) and a se
ﬂuorescence) and tyrosine hydroxylase staining (red ﬂuorescence) of presynaptic varicositie
innervation (orange ﬂuorescence) in (E) and no detectable tyrosine hydroxylase staining in
magniﬁcation insets of (E) and (F) illustrating speciﬁc synaptophysin labeled varicosities (gr
labeled varicosities (orange ﬂuorescence denoted by white arrows) in (G) and speciﬁc synap
culture in(H). Scale bar=25 μm.visible along the artery, no tyrosine hydroxylase immunoﬂuorescence
was observed, (Figs. 7F, H).
Discussion
Regional differences in vascular sympathetic innervation exist
among arteries and veins (Fleming et al., 1989; Grasby et al., 1999;
Grifﬁth et al., 1982) suggesting that vascular-derived cues may drive
axons to grow towards and ultimately innervate particular vessels.
During development, axons extend growth cones that “interrogate”
the environment for gradients of guidance cues that determine their
direction of growth (Kolodkin, 1996; Tessier-Lavigne and Goodman,
1996). We developed an in-vitro 3D co-culture system to evaluate
directed sympathetic neurite outgrowth towards both innervated and
non-innervated arteries and to investigate the effects of endogenous
attractive and repulsive gradients in determining patterns of neurite
outgrowth. Our results demonstrate an increased axon outgrowth
towards innervated arteries in-vivo, suggesting that these vessels
produce chemoattractants and non-innervated arteries produce
chemorepellants or different ratios of attractants and repellants that
together may inﬂuence vascular innervation patterns. Our study
identiﬁed VEGF-A and Semaphorin3A as chemoattractive and che-
morepulsive cues respectively for sympathetic neurons. We have used
our 3D co-culture to investigate the roles VEGF-A and Sema3A play in
modulating selective sympathetic neuronal outgrowth towards
vessels during development.
As axons extend towards their targets, they often travel along
vessels, which express guidance factors including NT-3 and artemin
(Belliveau et al., 1997; Damon, 2006; Damon et al., 2007). Sympathetic
nerves that do interact with vessels do not form traditional synaptic
terminals with vessels, but instead release neurotransmitter at
periodic synaptic varicosities (see Fig. 1).sympathetic axons growing towards femoral (A) or carotid (B) artery segments for ﬁve
l in 6/7 co-cultures. In addition, the neurons appeared to make contact with and wrap
l similar to that seen in ex-vivo whole mount preparations (data not shown). Scale
plants cultured with femoral (C) or carotid (D) artery segments for ﬁve days in 2.5 mg/
endicular to the vessel axis, investing the vessel, while neurons comprising the carotid
rating past the vessel segment (arrows) in 5/7 co-cultures. Scale bar=200 μm. (E, F)
gment of femoral artery cultured alone (F), illustrating synaptophysin staining (green
s, revealing co-localization of a portion of the varicosities suggestive of sympathetic re-
the mono-cultured femoral artery segment (F). Scale bar=100 μm. (G, H) High power
een ﬂuorescence denoted by black arrows) and synaptophysin/tyrosine hydroxylase co-
tophysin labeled varicosities (green ﬂuorescence denoted by black arrows) in the mono-
Fig. 8. Working model for the role of vascular-derived VEGF-A and Sema3A in
modulating sympathetic axon outgrowth. (A) Schematic representing ourmodel for the
roles of VEGF-A and Sema3A in modulating sympathetic outgrowth. Both VEGF-A and
Sema3A bind to Nrp1 and promote its association with a co-receptor, either VEGFR2 or
PlexinA1. Both femoral and carotid arteries produce VEGF-A. (B) The femoral artery was
noted to produce slightly more VEGF-A than the carotid artery. In the absence of
chemorepulsive signals, femoral-derived VEGF-A can bind to Nrp1, which can then
associate with VEGFR2, resulting in increased neurite outgrowth. (C) In contrast, the
carotid artery was noted to produce approximately three times more Sema3A than the
carotid artery, favoring Nrp1-bound Sema3A to associate with PlexinA1, resulting in
blunted neurite outgrowth.
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vation occurs. Previous studies inmouse have shown that sympathetic
target innervation occurs between embryonic day 8 (E8) and
postnatal day 20 (P20) (Glebova and Ginty, 2005). We observed
signiﬁcant increases in femoral innervation between P0–3, after
which innervation densities are not different from adult. Thuswe used
P2 SCG, a time-point when signiﬁcant vascular sympathetic innerva-
tion occurs and the animals are large enough to reproducibly dissect
tissues for analysis.
In-vivo, axons follow complex gradients of long and short-range
guidance cues and associate with extracellular matrix molecules in a
three-dimensional environment (Kolodkin, 1996). A 3D in-vitro
culture may better recapitulate the in-vivo complexity compared to
traditional two-dimensional cultures. By incorporating both inner-
vated and non-innervated vessels in culturewith SCGwe canmaintain
both attractive and repulsive gradients that together may determine
patterns of axon outgrowth and target innervation in-vivo (Fig. 2). Our
SCG explants cultured with single or both vessels showed increased
outgrowth towards the femoral artery compared to the carotid (Figs.
2C and D). In addition, the carotid artery is capable of disrupting the
increased axon outgrowth towards the femoral artery, suggesting that
these arteries may produce chemoattractant and chemorepulsive cues
whose ratios modulate differences in outgrowth and that the amount
of carotid-derived chemorepellant may more directly inﬂuence
patterns of neurite outgrowth (Fig. 2D).
While quantitative real-time PCR reveals that femoral arteries
express more VEGF-A and the carotid expresses more Sema3A,
Western blot analysis revealed that VEGF-A expression is not
signiﬁcantly different between the vessels, consistent with post-
translational modiﬁcations affecting protein expression. In addition,
sympathetic neurons express receptors for both guidance cues and
there is no difference in localization of receptors in SCG cultured alone
or in combination with innervated or non-innervated vessels. Given
these ﬁndings, it is plausible that in-vivo vascular-derived VEGF-A and
Sema3A may both modulate sympathetic axon outgrowth by
differential signaling through Nrp-1, which can interact with
VEGFR2 and Plexin1A, depending upon its counter ligand (Fig. 8).
To further evaluate the role of VEGF-A, we utilized high-expressing
VEGF-A–LacZ mice, which ubiquitously express higher VEGF-A
compared towild-type littermates (Miquerol et al., 2000). ByWestern
blot and qRT-PCR, VEGF-A (hi/+) femoral and carotid arteries express
approximately 40% more VEGF-A. In VEGF-A (hi/+) mice there is a
modest signiﬁcant increase in femoral artery TH immunoﬂuorescence,
suggesting that VEGF-A level may play a role in determining
sympathetic vascular innervation in-vivo. In-vitro 3D co-culture
experiments using VEGF-A (hi/+) carotid artery segments with
both wild-type and VEGF-A (hi/+) femoral segments suggest that
increased carotid VEGF-A expression mutes normal carotid-derived
growth inhibitory cues. In contrast, VEGF-A (hi/+) femoral artery
segments were unable to increase axon length when used in-vitro
with wild-type carotid arteries, suggesting a concentration-depen-
dent behavior consistent with previous studies in which distinct
concentration ranges of VEGF-A elicited speciﬁc cellular behaviors
(Enciso et al., 2003; Pinter et al., 2001). This suggests that endogenous
carotid-derived Sema3Amay repress the outgrowth effects of VEGF-A,
but increasing carotid VEGF-A expression decreases the Sema3A/
Nrp1/Plexin1A signaling, allowing VEGF-A to promote enhanced
outgrowth. Additionally, alginate spheres containing either 1.25% w/v
or 2.5% w/v VEGF-A (Jay et al., 2008) induced signiﬁcant increases in
average axon length towards the VEGF-A gradient. However, increas-
ing VEGF-A delivery by approximately 55% in-vitro by using 5% and
10% w/v VEGF-A alginate spheres did not elicit increased neurite
outgrowth, suggesting again that cellular responsiveness to VEGF-A
may fall within a narrow range (Enciso et al., 2003; Hallaq et al., 2004;
Pinter et al., 2001; Rosoff et al., 2004). To ensure VEGF-A speciﬁcity,
VEGF-A-neutralizing antibodies and a cell-speciﬁc VEGFR2 inhibitorwere used to block sphere- and femoral artery-promoted outgrowth.
Interestingly, while the inhibitor was able to decrease overall axon
length in a dose-dependent manner, for a given concentration, the
ratio of vessel/non-vessel average axon length was similar to control
cultures. This may be due to an alternate signaling pathway activated
by VEGF-A, such as via VEGFR1 signaling, which has been implicated
in regulating sympathetic growth cone area (Marko and Damon,
2008). However, the use of VEGFR1 function-blocking antibodies was
unable to decrease axon length or the increased outgrowth towards
the femoral artery. Although these data are in contrast to previous
studies (Marko and Damon, 2008) current studiesmay reﬂect species-
speciﬁc differences or alterations in signaling between two- and
three-dimensional cultures. In addition, while Nrp1-VEGFR1 interac-
tions have been reported, the function of this complex is not known.
In-vitro studies have demonstrated that Nrp1-VEGFR1 interactions
inhibit VEGF-A binding to VEGFR1, thereby antagonizing VEGF-A
signaling (Fuh et al., 2000). Alternatively, there may be other femoral-
derived growth factors that play a role in regulating axon outgrowth.
Multiple guidance cues may be present along an axon's trajectory
towards its target and create a “passageway” through which the axon
must navigate. In ours and previous studies, in the absence of VEGF-A
or Sema3A signaling, signiﬁcant baseline SCG outgrowth occurs,
which supports this concept (Damon, 2006; Marko and Damon,
2008). Future evaluation of the expression proﬁle of innervated vs.
non-innervated vessels may help shed light on these additional
factors.
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promoting sympathetic neurite outgrowth (Marko and Damon,
2008). Our data revealed that while there is no signiﬁcant difference
in VEGF-A protein expression between vessels, the carotid expresses
signiﬁcantly more Sema3A compared to femoral arteries. This
suggests that in-vivo the amount of Sema3A present in the
environment may play a signiﬁcant role in modulating sympathetic
outgrowth patterns in these vessels as Sema3A has been implicated
in sympathetic neuron outgrowth (Chen et al., 1998; Damon, 2006;
Kawasaki et al., 2002; Suto et al., 2005). We conducted co-culture
experiments using chimeric recombinant human Sema3A/Fc-encap-
sulated alginate spheres and as with VEGF-A, Sema3A spheres
inﬂuenced neurite outgrowth in a dose-dependent manner with
the largest reduction in outgrowth observed with a 2.5% w/v sphere.
In addition, a similar loss of responsiveness at the highest Sema3A
concentration was observed which supports previous reports of a
narrow concentration range within which axons respond to chemical
gradients (Rosoff et al., 2004).
To investigate whether gradients of VEGF-A and Sema3A
combinatorially affect neurite outgrowth, dual sphere co-cultures
were performed using VEGF-A and Sema3A/Fc spheres of equal
concentrations within the responsive range (1.25% or 2.5% w/v)
placed on opposite sides of the SCG. The results of these
experiments were identical to single sphere co-cultures, suggesting
that when these two molecules are present in similar concentrations
(w/v) creating opposing gradients, neither molecule predominates.
In additional experiments utilizing function-blocking antibodies
speciﬁc to Nrp1 elicited decreased overall axon length in SCG
explants, conﬁrming that Nrp1 signaling plays a role in sympathetic
axon outgrowth. In femoral–SCG–carotid co-cultures, blocking Nrp1
both decreased overall axon outgrowth and also eliminated the
difference in outgrowth towards one vessel compared to another.
This leads to the hypothesis that while VEGF signaling through
VEGFR2 may play an important role in promoting increased axon
outgrowth towards innervated vessels, Sema3a-Nrp1 signaling in
dual vessel co-cultures may play the predominant role in determin-
ing overall patterns of outgrowth. In addition, Nrp1 antibodies
blocked both the increase in outgrowth elicited by the femoral
artery and the decrease in outgrowth elicited by the carotid artery in
both single vessel co-cultures and femoral–SCG–carotid co-cultures,
further suggesting that both VEGF-A/Nrp1 and Sema3A/Nrp1
signaling is at play in postnatal day 2 SCG. However, a higher
concentration of antibody was required to reduce the blunting effect
of the carotid artery, suggesting that there may be signiﬁcantly
different kinetics between VEGF-Nrp1 and Sema3A-Nrp1 signaling
or possible that the carotid artery produces more Sema3A than was
able to be neutralized by the antibody. Additional experiments
investigating the afﬁnity and binding kinetics of these two ligands
for Nrp1 will be necessary to more deﬁnitively deﬁne the individual
roles of VEGF-A and Sema3A in regulating sympathetic axon
outgrowth.
In-vivo sympathetic nerves may encounter overlapping gradients
of guidance cues. Combinations of such gradients may be necessary
for sympathetic nerves to properly ﬁnd and innervate ﬁnal targets.
Previous studies have demonstrated that the balance of VEGF-A and
Sema3A may inﬂuence particular cellular responses (Vieira et al.,
2007; Schwarz et al., 2004). Our data shows that both the femoral and
carotid arteries express signiﬁcant VEGF-A, but only the carotid
expresses signiﬁcant Sema3A, suggesting that sympathetic growth
cones may detect the higher Sema3A levels within the VEGF-A
gradient. Hence, the increased Sema3A molecules may result in
increased Sema3A–Nrp1 binding, eliciting increased Nrp1–Plexin
interaction and intracellular signaling, resulting in decreased axon
outgrowth. To evaluate the effect of overlapping gradients, we placed
both VEGF-A and Sema3A spheres on the same side of the SCG and
measured neurite outgrowth. Our ﬁnding that increases in Sema3Aconcentration block the growth promoting effects of VEGF-A suggests
that the presence of increasing concentrations of Sema3A may be able
to elicit increased Sema3A–Nrp1–PlexinA1 and thus may be a
determining factor that limits sympathetic neurite outgrowth when
both molecules are present in the extracellular environment.
Our data suggests that vascular-derived VEGF-A and Sema3A
inﬂuence sympathetic outgrowth in-vitro and together may in part
determine patterns of vascular sympathetic outgrowth in-vivo during
development. To evaluate whether femoral and carotid-derived cues
not only promote variations in axon outgrowth but differential
innervation of vessels, we performed ﬁve-day neurovascular co-
cultures to determine whether axons would innervate femoral and/or
carotid arteries. While axons extended to both vessels, in carotid
arteries axons grew past the vessel and appeared to grow across the
vessel surface. In contrast, sympathetic axons rarely grew past femoral
artery segments and instead formed an elaborate mesh of axons
around the vessel, similar to what we observed ex-vivo, suggesting
that these axons were potentially re-innervating the vessel. Further
studies would allow us to determine whether these axons made
functional contacts with the vessels and will shed light on the
molecules responsible for this differential response.
Our data demonstrates that while both innervated and non-
innervated vessels produce chemoattractive molecules (VEGF-A),
non-innervated vessels may produce signiﬁcantly more chemorepul-
sive factors (Sema3A). Thus, gradients of guidance cues may work in
combination to direct outgrowth and ultimate innervation patterns.
Increased carotid Sema3A expression may blunt the effect of VEGF-A,
therefore playing a predominant role in regulating sympathetic axon
outgrowth when both molecules are present (Fig. 8). It is also likely
that other signaling pathways are involved in-vivo as nearby cells or
tissues likely produce additional cues that direct axonal growth cones
away from non-innervated vessels or produce alternate cues that
strengthen the chemorepulsive cues that originate from the vessels
themselves.
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